The Alliance for Regenerative Medicine (ARM) has released its first quarter industry report that describes a regenerative medicine sector, which includes gene and cellular therapies, in healthy shape. Growth is evident on a number of fronts, even in the wake of the uncertain financial environment that has prevailed and depressed the capital market since the beginning of the year.